Discovery and development of GSK3 inhibitors for the treatment of type 2 diabetes

Current Pharmaceutical Design

Volumn 10, Issue 10, 2004, Pages 1105-1138

  Wagman, Allan S ^a   Johnson, Kirk W ^b   Bussiere, Dirksen E ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b Genesoft Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,3,4 OXADIAZOLE DERIVATIVE; 12 (2 CYANOETHYL) 6,7,12,13 TETRAHYDRO 13 METHYL 5 OXOINDOLO[2,3 A]PYRROLO[3,4 C]CARBAZOLE; 2 [1 (3 AMIDINOTHIOPROPYL) 1H INDOL 3 YL] 3 (1 METHYL 1H INDOL 3 YL)MALEIMIDE; ALSTERPAULLONE; AMINOPYRIDINE DERIVATIVE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; ANTIDIABETIC AGENT; CEVIMELINE; CT 20026; CT 99021; CYCLIN DEPENDENT KINASE INHIBITOR; DIACETYLDEBROMOHYMENIALDISINE; DIACETYLHYMENIALDISINE; ENZYME INHIBITOR; FURAZAN DERIVATIVE; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3BETA; HYDANTOIN DERIVATIVE; HYMENIALDISINE; IMIDAZOLE DERIVATIVE; INDIRUBIN; INSULIN; KENPAULLONE; KT 5823; MALEIMIDE DERIVATIVE; MUSCARINIC AGENT; PAULLONE; PAULLONE DERIVATIVE; PHOSPHOTRANSFERASE INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

DIABETES CONTROL; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG DETERMINATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SPECIFICITY; ENZYME STRUCTURE; GENETIC TRANSCRIPTION; GLUCOSE TRANSPORT; GLYCOGEN METABOLISM; GLYCOGEN SYNTHESIS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INSULIN RESISTANCE; METABOLIC REGULATION; METABOLIC SYNDROME X; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; REVIEW; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DRUG DESIGN; ENZYME INHIBITORS; GLYCOGEN SYNTHASE KINASE 3; HUMANS; HYPOGLYCEMIC AGENTS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; SUBSTRATE SPECIFICITY;

EID: 1842588303     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612043452668     Document Type: Review

References (222)

1. Wagman AS, Nuss JM. Current therapies and emerging targets for the treatment of diabetes. Cur Pharm Des 2001; 7(6): 417-450.
2. Eldar-Finkelman H. Glycogen synthase kinase 3: An emerging therapeutic target. Trends Mol Med 2002; 8(3): 126-132.
3. Saltiel AR. New perspectives into the molecular pathogenesis and treatment of type 2 diabetes. Cell 2001; 104: 517-529.
4. Cross D, Alessi D, Vandenheede J, Mcdowell H, HUndal H, Cohen P. Tile inhibition of glycogen synthase kinase-3 by insulin or insulin-like growth factor 1 in the rat skeletal muscle cell line L6 is blocked by wortmannin, but not by rapamycin: Evidence that wortmannin blocks activation of the mitogen-activated protein kinasc pathway in L6 cells between Ras and Raf. Biochem J 1994; 303: 21-60.
5. Welsh GI, Proud CG. Glycogen synthase kinase-3 is rapidly inactivated in response to insulin and phosphorylates eukaryotic initiation factor eIF-2B. Biochem J 1993; 294: 625-629.
6. Moule SK, Welsh GI, Edgell NJ, Foulstone EJ, Proud CG, Denton RM. Regulation of protein kinase B and glycogen synthase kinase-3 by insulin and β-adrenergic agonists in rat epididymal fat cells. Activation of protein kinase B by Wortmannin-sensitive and - insensitive mechanisms. J Biol Chem 1997; 272: 7713-7719.
7. Woodgett JR. cDNA cloning and properties of glycogen synthase kinase-3. Methods Enzymol 1991; 200: 564-577.
8. Ali A, Hoeflich KP, Woodgett JR. Glycogen synthase kinase-3-properties, functions, and regulation. Chem Rev 2001; 101: 2527-2540.
9. Frame S, Cohen P. GSK3 takes centre stage more than 20 years after its discovery. Biochem J 2001; 359(1): 1-16.
10. Kaidanovich O, Eldar-Finkelman, H. The role of glycogen synthase kinase-3 in insulin resistance and type 2 diabetes. Expert Opin Ther Targets 2002; 6: 555-561.
11. Shaw PC, Davies AF, Lau KF, Garcia-Barcelo M, Waye MM, Lovestone S, et al. Anderton BH. Isolation and chromosomal mapping of human glycogen synthase kinase-3α and -3β encoding genes. Genome 1998; 41: 720-727.
12. Wehrli M, Dougan ST. Caldwell K, O'Keefe L, Schwartz S, Vaizel-Ohayon D, et al. Arrow encodes an LDL-receptor-related protein essential for wingless signalling. Nature 2000; 407(6803): 527-530.
13. Eldar-Finkelman H, Agrast GM, Foord O, Fischer EH, Krebs EG. Expression and characterization of glycogen synthase kinase-3 mutants and their effect oil glycogen synthase activity. Proc Natl Acad Sci USA 1996; 93: 10228-10233.
14. Summers SA, Kao AW, Kohn AD, Backus GS, Roth RA, Pessin JE, Birnbaum MJ. The role of glycogen synthase kinase 3beta in insulin-stimulated glucose metabolism. J Biol Chem 1999; 274(25): 17934-17940.
15. Tanti JF, Gremeaux T, Van Obberghen E, Le Marchandbrustel Y. Serine/threonine phosphorylation of insulin receptor substrate 1 modulates insulin receptor signaling. J Biol Chem 1994; 269: 6051-6057.
16. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman, BM. IRS-1 mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha and obesity induced insulin resistance. Science 1996; 271: 665-658.
17. Eldar-Finkelman H, Krebs EG. Phosphorylation of insulin receptor Substrate-1 by glycogen synthase kinase-3 impairs insulin action. Proc Natl Acad Sci 1997; 94: 9660-9664.
18. Morfini G, Szebenyi G, Elluru R, Ratner N, Brady ST. Glycogen synthase kinase 3 phosphorylates kinesin light chains and negatively regulates kinesin-based motility. EMBO J 2002; 21: 281-293.
19. Emoto M, Langille SE, Czech MP. A role for kinesin in insulin-stimulated GLUT4 glucose transporter translocation in 3T3-L1 adipocytes. J Biol Chem 2001; 276: 10677-10682.
20. Woodgett JR. Molecular cloning and expression of glycogen synthase kinase-3/factor A. EMBO J 1990; 9: 2431-2438.
21. Shaw PC, Davies AF, Lau KF, Garcia-Barcelo M, Waye MM, Lovestone S, et al. Isolation and chromosomal mapping of human glycogen synthase kinase-3α and -3β encoding genes. Genome 1998; 41: 720-727.
22. Lau KF, Miller CC, Anderton BH, Shaw PC. Expression analysis of glycogen synthase kinase-3 in human tissues. J Pept Res 1999; 54: 85-91.
23. Mukai F, Ishiguro K, Sano Y, Fujita SC. Alternative splicing isoform of tau protein kinase I/glycogen synthase kinase 3β. J. Neurochem 2002; 81: 1073-1083.
24. Sutherland C, Leighton IA, Cohen P. Inactivation of glycogen synthase kinase-3β by phosphorylation: New kinase connections in insulin and growth-factor signalling. Biochem J 1993; 296: 15-19.
25. Hughes K, Nikolakaki E, Plyte SE, Totty NF, Woodgett JR. Modulation of the glycogen synthase kinase-3 family by tyrosine phosphorylation. EMBO J 1993; 12: 803-808.
26. Wang QM, Fiol CJ, DePaoli-Roach AA, Roach PJ. Glycogen synthase kinase-3β is a dual specificity kinase differentially regulated by tyrosine and serine/threonine phosphorylation. J Biol Chem 1994; 269: 14566-14574.
27. A comprehensive listing of all references investigating GSK3 homologs would be too numerous to list here. An excellent review covering this subject is: Ali A, Hoeflich, KP, Woodgett JR. Glycogen Synthase Kinase-3: Properties, Functions, and Regulation. Chem Rev 2001; 101: 2527-2540.
28. Angerer LM, Angerer RC. Animal-vegetal axis patterning mechanisms in the early sea urchin embryo. Dev Biol 2000; 218: 1-12.
29. Emily-Fenouil F, Ghiglione C, Lhomond G, Lepage T, Gache C. GSK3β/shaggy mediates patterning along the animal-vegetal axis of the sea urchin embryo. Development 1998; 125: 2489-2498.
30. Insall R. Glycogen synthase kinase and Dictyostelium development: Old pathways pointing in new directions? Trends Genet 1995; 11: 37-39.
31. Plyte SE, O'Donovan E, Woodgett JR, Harwood AJ. Glycogen synthase kinase-3 (GSK-3) is regulated during Dictyostelium development via the serpentine receptor cAR3. Development 1999; 126: 325-333.
32. Huang KP, Itarte E, Singh TJ, Akatsuka A. Phosphorylation of glycogen synthase by cyclic AMP-independent casein kinase-2 from rabbit skeletal muscle. J Biol Chem 1982; 257: 3236-3242.
33. Dajani R, Fraser E, Roe SM, Young N, Good V, Dale TC, Pearl LH. Crystal structure of glycogen synthase kinase 3β: Structural basis for phosphate-primed substrate specificity and autoinhibition. Cell 2001; 105: 721-732.
34. ter Haar E, Coll JT, Austen DA, Hsiao HM, Swenson L, Jain J. Structure of GSK3β reveals a primed phosphorylation mechanism. Nat Struct Biol 2001; 8: 593-596.
35. Bussiere DE, He M, Le VP, Jansen JM, Chin SM, Martin E. (Chiron Corporation, USA) Crystallization and crystal structure of human glycogen synthase kinase 3β protein and methods of use thereof. WO 0224893 A2 20020328, 2002; 200 pp.
36. Bax B, Carter PS, Lewis C, Guy AR, Bridges A, Tanner R, et al. The Structure of Phosphorylated GSK-3β Complexed with a Peptide, FRATtide, that Inhibits β-Catenin Phosphorylation. Structure 2001; 9: 1143-1152.
37. Dajani R, Fraser E, Roe SM, Yeo M, Good VM, Thompson V, et al. Structural basis for recruitment of glycogen synthase kinase 3β to the axin-APC scaffold complex. EMBO J 2003; 22(3): 494-501.
38. An excellent review of the structural basis for GSK3 function is Pearl LH, Barford D. Regulation of protein kinases in insulin, growth factor and Wnt signalling. Curr Opin Struct Biol 2002: 12: 761-767.
39. Thomas GM, Frame S, Goedert M, Nathke I, Polakis P, Cohen P. A GSK3-binding peptide from FRAT1 selectively inhibits the GSK3-catalyzed phosphorylation of Axin and β-catenin. FEBS Lett 1999, 458, 247-251.
40. Liu C, Li Y, Semenov M, Han C, Baeg GH, Tan Y, et al. Control of β-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell 2002; 108: 837-847.
41. Yanagawa S, Matsuda Y, Lee JS, Matsubayashi H, Sese S, Kadowki T, et al. Casein kinase 1 phosphorylates the Armadillo protein and induces its degradation in Drosophila. EMBO J 2002; 21: 1733-1742.
42. Madhusudan PA, Xuong NH, Taylor SS. Crystal structure of a transition state mimic of the catalytic subunit of cAMP-dependent protein kinase. Nat Struct Biol 2002; 9(4): 273-277.
43. Johnson LN, Noble MEM, Owen DJ. Active and inactive protein kinases: Structural basis for regulation. Cell 1996; 85: 149-158.
44. An excellent review of the structural basis for GSK3 function is Pearl LH, Barford D. Regulation of protein kinases in insulin, growth factor and Wnt signalling. Curr Opin Struct Biol 2002; 12: 761-767.
45. Frame S, Cohen P, Biondi RM. A common phosphate binding site explains the unique substrate specificity of GSK3 and its inactivation by phosphorylation. Mol Cell 2001; 7: 1321-1327.
46. Sawyer TK, Bohacek RS, Metcalf III CA, Shakespeare WC, Wang Y, Sundaramoorthi R, et al. Novel protein kinase inhibitors: SMART drug design technology. Biotechniques 2003; 34: S2-S15.
47. See for example Hardcastle IR, Golding BT, Griffin RJ. Designing inhibitors of cyclin-dependent kinases. Annu Rev Pharmacol Toxicol 2002; 42: 325-348.
48. Gould C, Wong CF. Designing specific protein kinase inhibitors: Insights from computer simulations and comparative sequence/structure analysis. Pharmacol Ther 2002; 93(2-3): 169-178.
49. Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J. Structural mechanism For STI-571 inhibition of Abelson tyrosine kinase. Science 2002; 289(5486): 1938-1942.
50. Tong LS, Pav S, White DM, Rogers S, Crane KM, Cywin CL, et al. A highly specific inhibitor of human p38 MAP kinase binds in the ATP pocket Nat Struct Biol 1997; 4: 311-316.
51. Sawyer TK, Bohacek RS, Dalgarno DC, Eyermann CJ, Kawahata N, Metcalf III CA, et al. Src homology-2 inhibitors: Peptidomimetic and nonpeptide. Mini Rev Med Chem 2002; 2(5): 475-488.
52. Chen J, Fang Y. A novel pathway regulating the mammalian target of rapamycin (mTOR) signaling. Biochem Pharmacol 2002; 64: 1071-1077.
53. Huang S, Houghton PJ. Inhibitors of mammalian target of rapamycin as novel antitumor agents: From bench to clinic. Curr Opin Investig Drugs 2002; 3: 295-304.
54. Parang K, Till JH, Ablooqlu AJ, Kohanski RA, Hubbard SR, Cole PA. Mechanism-based design of a protein kinase inhibitor. Nat Struct Biol 2001; 8(1): 37-41.
55. Parang K, Cole PA. Designing bisubstrate analog inhibitors for protein kinases. Pharmacol Ther 2002; 93(2-3): 145-157.
56. Tsai HL, Harlow E, Meyerson M. Isolation of the human cdk2 gene that encodes the cyclin A- and adenovirus E1A-associated p33 kinase. Nature 1991; 353: 174-177.
57. Meyerson M, Enders GH, Wit CL, Su LK, Gorka C, Nelson C, et al. A family of human cdc2-related protein kinases. EMBO J 1992; 11: 2909-2917.
58. Ding VW, Chen RH, McCormick F. Differential regulation of glycogen synthase kinase 3β by insulin and Wnt signaling. J Biol Chem 2000; 275: 32475-32481.
59. Lustig B, Behrens J. The Wnt signaling pathway and its role in tumor development. J. Cancer Res Clin Oncol 2003; 129: 199-221.
60. Kim L, Kimmel AR. GSK3, a master switch regulating cell-fate specification and tumorigenesis. Curr Opin Genet & Devel 2000; 10: 508-514.
61. Rubinfeld B, Tice DA, Polakis P. Axin-dependent phosphorylation of the adenomatous polyposis coli protein mediated by casein kinase 1E J Biol Chem 2001; 276: 39037-39045.
62. Yamamoto H, Kishida S, Kishida M, Ikeda S, Takada S, Kikuchi A. Phosphorylation of axin, a Wnt signal negative regulator, by glycogen synthase kinase-3β regulates its stability. J Biol Chem 1999; 274: 10681-10684.
63. Rubinfeld B, Albert I, Porfiri E, Fiol C, Munemitsu S, Polakis P. Binding of GSK3β to the APC-β-catenin complex and regulation of complex assembly. Science 1996; 272: 1023-1026.
64. Jiang J, Struhl G. Regulation of the Hedgehog and Wingless signaling pathways by the F-box/WD40-re peat protein Slimb. Nature 1998; 391: 493-496.
65. Maniatis T. A ubiquitin ligase complex essential for the NF-κB, Wnt/wingless, and hedgehog signaling pathways. Genes Dev 1999; 13: 505-510.
66. Li L, Yuan H, Weaver CD, Mao J, Farr GH, Sussman DJ, et al. Axin and Frat1 interact with Dvl and GSK, bridging Dvl to GSK in Wnt-mediated regulation of LFF-1. EMBO J 1999; 18: 4233-4240.
67. Eastman Q, Grosschedl R. Regulation of LEF-1/TCF transcription Factors by Wnt and other signals. Curr Opin Cell Biol 1999; 11: 233-240.
68. Huber AH, Weis WI. The structure of the β-catenin/E-eadherin complex and the molecular basis of diverse ligand recognition by β-catenin. Cell 2001; 105(3): 391-402.
69. Elof-Spink K, Fridman SG, Weis WI. Molecular mechanisms of β-catenin recognition by adenomatous polyposis coli revealed by the structure of an APC-β-catenin complex. EMBO J 2001; 20(22): 6203-6212.
70. Poy F, Lepourcelet M, Shivdasani RA, Eck MJ. Structure of a human Tcf-β-catenin complex. Nat Struct Biol 2001; 8(12): 1053-1057.
71. Thomas GM, Frame S, Goedert M, Nathke I, Polakis P, Cohen P. A GSK3-binding peptide from FRAT1 selectively inhibits the GSK3-catalyzed phosphorylation of Axin and β-catenin. FEBS Lett 1999; 458(2): 247-251.
72. Fraser E, Young N, Dajan R, Franca-Koh J, Ryves J, Williams RSB, et al. Identification of the Axin and Frat binding region of glycogen synthase kinase-3. J Biol Chem 2003; 277(3): 2176-2185.
73. Cohen P. Protein kinases - the major drug targets of the twenty-first centry? Nat Rev Drug Disc 2002; 1: 309-315.
74. Bullock WH, Magnuson SR, Choi S, Gunn DE, Rudolph J. Prospects for kinase activity modulators in the treatment of diabetes and diabetic complications. Curr Topics Med Chem 2002; 2(9): 915-938.
75. Cohen P, Frame S. Timeline: The renaissance of GSK3. Nat.Rev Mol Cell Biol 2001; 2(10): 769-776.
76. Martinez A, Castro A, Dorronsoro I, Alonso M. Glycogen synthase kinase 3 (GSK3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer and inflammation. Med Res Rev 2002; 22: 373-384.
77. Dorronsoro I, Castro A, Martinez A. Inhibitors of glycogen synthase kinase-3: Future therapy for unmet medical needs? Expert Opin Ther Patents 2002; 12(10): 1527-1536.
78. Stambolic V, Ruel L, Woodgett JR. Lithium inhibits glycogen synthase kinase-3 activity and mimics Wingless signalling in intact cells. Curr Biol 1996; 6: 1664-1668.
79. Klein, PS, Melton DA. A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci USA 1996; 93: 8455-8459.
80. Williams RSB, Harwood AJ. Lithium therapy and signal transduction. Trends Pharmacol Sci 2000; 21: 61-64.
81. Phiel C J, Klein PS. Molecular targets of lithium action. Ann Rev Pharm Tox 2001; 41: 789-813.
82. Jope RS. Anti-bipolar therapy: Mechanism of' action of lithium. Mol Psychiatry 1999, 4(2), 117-128.
83. Agam G, Levine J. Glycogen synthase kmase-3 - a new target for lithium's effects in bipolar patients? Human Psychopharm 1998; 13(7): 463-465.
84. Chen G, Huang LD, Jaing YM, Manji HK. The mood-stablizing agent Valproate inhibits the activity of GSK3. J Neurochem 63; 2361-4.
85. Gould TD, Manji HK. The Wnt signaling pathway in bipolar disorder. Neuroscientist 2002; 8(5): 497-511.
86. Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, Klein PS. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 2001; 276: 36734-36741.
87. Blaheta RA, Cinatl J, Jr. Anti-tumor mechanisms of valproate: a novel role for an old drug. Med Res Rev 2002; 22(5): 492-511.
88. Lovestone S, Davis DR, Webster MT, Kaech S, Brion JP, Matus A, et al. Lithium reduces tau phosphorylation: Effects in living cells and in neurons at therapeutic concentrations. Biol Psychiatry 1999; 45: 995-1003.
89. Bhat RV, Budd SL. GSK3 beta Signalling: Casting a Wide Net in Alzheimer's Disease. Neurosignals 2002; 11(5): 251-261.
90. Planel E, Sun X, Takashima A. Role of GSK3.beta, in Alzheimer's disease pathology. Drug Dev Res 2002; 56(3): 491-510.
91. Kaytor MD, Orr HT. The GSK3.beta. signaling cascade and neurodegenerative disease. Curr Opin Neurobiol 2002; 12(3): 275-278.
92. De Ferrari GV, Inestrosa NC. Wnt signaling function in Alzheimer's disease. Brain Res Rev 2000; 33(1): 1-12.
93. Davies SP, Reddy H, Caivanoã M, Cohen P. Specificity And Mechanism Of Action Of Some Commonly Used Protein Kinase Inhibitors. Biochem J 2000; 351: 95-105.
94. Bain J, McLauchlan H, Elliott M, Cohen P. The specificities of protein kinase inhibitors: An update. Biochem J 2003; 371: 199-204.
95. Tang W, Eisembrand G. Chinese Drugs of plant origin: Chemistry, Pharmacology, and Use in Traditional and Modern Medicine. Springer-Verlag: Heidelberg 1998.
96. Hoessel R, Leclerc S, Endicott JA, Nobel ME, Lawrie A, Tunnah P, et al. Indirubin, the active constituent of a chinese antileukaemia medicine, inhibits cyclin-dependent kinases. Nat Cell Biol 1999; 1: 60-67.
97. Leclerc S, Garnier M, Hoessel R, Marko D, Bibb JA, Snyder GL, et al. Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors? J Biol Chem 2001; 276: 251-260.
98. Zaharevitz DW, Gussio R, Leost M, Senderowicz AM, Lahusen T, Kunick C, et al. Discovery and initial characterization of the paullones, a novel class of small-molecule inhibitors of cyclin-dependent kinases. Cancer Res 1999; 1: 60-67.
99. Schultz C, Link A, Leost M, Zaharevitz DW, Gussio R, Sausville EA, et al. Paullones, a series of cyclin-dependent kinase inhibitors: Synthesis, evaluation of CDK1/Cyclin B inhibition, and in vitro antitumor activity. J Med Chem 1999; 42: 2909-2919.
100. Leost M, Schultz C, Link A, Wu YZ, Biernat J, Mandelkow EM, et al. Paullones are potent inhibitors of glycogen synthase kinase-3b and cyclin-dependent kinase 5/p25. Eur J Biochem 2000; 267: 5983-5994.
101. Pettit GR. Progress in the discovery of biosynthetic anticancer drugs. J Nat Prod 1996; 59: 812-821.
102. Boyd MR, Pettit, GR, McNulty J, Herald DL, Doubek DL, Chapuis J-C, et al. Antineoplastic agents. 362. Isolation and X-ray crystal structure of dibromophakellstatin from the Indian Ocean sponge Phakellia mauritiana. J Nat Prod 1997; 60(2): 180-183.
103. Breton JJ, Chabot-Fletcher MC. The natural product hymenaldisine inhibits interleukin-8 production in U937 cells by inhibition of nuclear factor-kB. J Pharmacol Exp Ther 1997, 282: 459-466.
104. Meijer L, Thunnissen AM, White AW, Garnier M, Nikolic M, Tsai LH, et al. Inhibition of cyclin-dependent kinases, GSK3beta and CK1 by hymenialdesine, a marine sponge constituent. Chem Biol 2000; 7: 51-63.
105. Meijer, Laurent. (Centre National de la Recherche Scientifique (CNRS), Fr.). Use of hymenialdisine or a derivative thereof as an inhibitor of cyclin-dependent kinases, GSK3.beta. and casein kinase 1, and therapeutic use. EP 1106180 A1 20010613, 2001; pp. 38.
106. Schultz P, Ring DB, Harrison SD, Bray AM. (Chiron Corporation, USA: Regents of the University of California) Preparation of purines as inhibitors of glycogen synthase kinase 3 (GSK3). WO 9816528 A1 19980423, 1998; pp. 27.
107. Norman TC, Gray NS, Koh JT, Schultz PG. A structure-based library approach to kinase inhibitors. J Am Chem Soc 1996; 118: 7430-7431.
108. Klein PS, Melton D. (Trustees of the University of Pennsylvania, USA; Presidents and Fellows of Harvard College) Inhibitors of glycogen synthase kinase-3 and methods for their identification and use. WO 9741854 A1 19971113, 1997, pp. 64.
109. Harrison SD, Ring DB. (Chiron Corporation, USA) Identification and use of selective inhibitors of glycogen synthase kinase 3 (GSK3) for therapeutic use. US 6057286 A 20000502, 2000; pp. 12.
110. Nuss JM, Harrison SD, Ring DB, Boyce RS, Brown SP, Goff D, Johnson K, Pfister KB, Ramurthy S, Renhowe PA, Seely L, Subramanian S, Wagman AS, Zhou XA. (Chiron Corporation, USA) Preparation of aminopyrimidines and -pyridines as glycogen synthase kinase 3 inhibitors. WO 9965897 A1 19991223, 1999; pp. 262.
111. Nuss JM, Harrison SD, Ring DB, Boyce RS, Johnson K, Pfister KB, et al. (Chiron Corporation, USA) Preparation of aminopyrimidines and -pyridines as glycogen synthase kinase 3 inhibitors. WO 0220495 A2 20020314, 2002; pp. 268.
112. Nuss JM, Ramurthy S. (Chiron Corp., USA) Pyrazine-based inhibitors of glycogen synthase kinase 3 (GSK3) useful as, e.g., antidiabetics. WO 0144206 A1 20010621, 2001; pp. 53.
113. Nuss JM, Zhou XA. (Chiron Corp., USA) Bicyclic inhibitors of glycogen synthase kinase 3. WO 0144246 A1 20010621, 2001; pp. 63.
114. Unpublished results. Details of the crystallographic studies, inhibitor/GSK3 protein co-crystals and binding interactions of this series of compounds will be published shortly.
115. Ring DB, Johnson KW, Henriksen EJ, Nuss JM, Goff D, Kinnick TR, et al. Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo. Diabetes 2003; 52(3): 588-595.
116. Wagman AS, Harrison SD, Johnson K, Ring DB, Bussiere DE, NUSS JM, et al. Antidiabetic glycogen synthase kinase 3 inhibitors: In vitro and in vivo activity. Abstracts of Papers, 225th ACS National Meeting, New Orleans, LA, USA, March 23-27, 2003; MEDI-022.
117. Wagman AS. Chiron Corp., Antidiabetic glycogen synthase kinase 3 inhibitors Gordon Conference, Medicinal Chemistry, August 2001.
118. Hanks SK, Hunter T. Protein kinases. 6. The eukaryotic protein kinase superfamily: Kinase (catalytic) domain structure and classification. FASEB J 1995; 9: 576-596.
119. Hers I, Tavare' JM, Denton RM. The protein kinase C inhibitors bisindolylmaleimide I (GF 109203x) and IX (Ro 31-8220) are potent inhibitors of glycogen synthase kinase-3 activity. FEBS Lett 1999; 460: 433-436.
120. Prudhomme M, Marminon C, Moreau P, Hickman J, Pierre A, Pfeiffer B, et al. (Les Laboratoires Servier, Fr.). Preparation of hydroxyalkyl-indolocarbazole glycosides as antidiabetics and glycogen synthase kinase inhibitors, FR 2831169 A1 20030425, 2003, pp. 28.
121. Lingameneni R, Vyotskaya TN, Duch DS, Hemmings HC. Inhibition of voltage-deperident sodium channels by Ro 31-8220, a "sPecific" protein kinase C inhibitor. FEBS Lett 2000; 473: 265-268.
122. Smith DG, Buffet M, Fenwick AE, Haigh D, Ife R, Saunders M, et al. 3-Anilino-4-arylmaleimides: Potent and selective inhibitors of glycogen synthase kinase-3 (GSK3). Bioorg Med Chem Lett 2001; 11: 635-639.
123. Coghlan MP, Fenwick AE, Haigh D, Holder JC, Ife RJ, Reith AD, et al. (Smithkline Beecham P.L.C., UK). Preparation of pyrroledione derivatives as inhibitors of glycogen synthase kinase-3. WO 0021927 A2 20000420, 2000; pp. 131.
124. Haigh D, Slingsby BP, Smith DG, Ward RW. (Smithkline Beecham P.L.C., UK). Pyrrole-2, 5-dione derivatives for the treatment of diabetes. WO 0174771 A1 20011011, 2001; pp. 67.
125. Coghlan MP, Holder JC, Reith AD, Smith DG. (Smithkline Beecham PLC, UK). Maleimide and carbazole derivatives for the treatment of conditions with a need for the inhibition of glycogen synthase kinase-3 (GSK3). WO 0038675 A1 20000706, 2000; pp. 28.
126. Coghlan MP, Culbert AA, Cross DAE, Corcoran SL, Yates JW, Pearce NJ, et al. Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. Chem Biol 2000; 7: 793-803.
127. Gong L, Grupe A, Peltz GA. (F. Hoffmann-La Roche A.-G. Switz.). Preparation of 3-indolyl-4-phenyl-1H-pyrrole-2, 5-dione derivatives as inhibitors of glycogen synthase kinase-3beta for therapeutic agents. WO 0210158 A2 20020207, 2002; pp. 105.
128. Lochhead PA, Coghlan M, Rice SQJ, Sutherland C. Inhibition of GSK3 selectively reduces glucose-6-phosphatase and phosphoenol-pyruvate carboxykinase gene expression. Diabetes 2001; 50, 1-10.
129. Cross DAE, Cubert AA, Chalmers KA, Facci L, Skaper SD, Reith AD. Selective small-molecule inhibitors of glycogen synthase kinase-3 activity protect primary neurones from death. J Neurochem 2001; 77: 94-102.
130. Doherty P, Eickholt BJ, Skaper SD, Walsh FS. (Smithkline Beecham P.L.C. UK). Nerve regeneration-associated treatment of neuronal injury conditions with glycogen synthase kinase 3 (GSK3) inhibitors. WO 02623 87 A1 20020815, 2002, pp. 22.
131. Culbert AA, Brown MJ, Frame S, Hagen T, Cross DA, Bax B, et al. GSK3 inhibition by adenoviral FRAT1 over-expression is neuroprotective and induces Tau dephosphorylation and beta-catetin stabilisation without elevation of glycogen synthase activity. FEBS Lett 2001; 507, 288-294.
132. Kuo G-H, Prouty C, DeAngelis A, Shen L, O'Neill DJ, Shah C, et al. Synthesis and Discovery of Macrocyclic Polyoxygenated Bis-7-azaindolylmaleimides as a Novel Series of Potent and Highly Selective Glycogen Synthase Kinase-3beta, Inhibitors. J Med Chem 2003; 46(19): 4021-4031.
133. Kuo G-H, Prouty C, Deangelis A, Zhang H-C. (Ortho-McNeil Pharmaceutical, Inc. USA). Preparation of bis(heterocyclyl) pyrrolinones and bis(heterocyclyl)pyrrolediones as inhibitors of kinases for the treatment of kinase-mediated diseases. WO 0246197 A1 20020613, 2002: Pp. 143.
134. Witherington J, Bordas V, Garland SL, Hickey DMB, Ife RJ, Liddle J, et al. 5-Aryl-pyrazolo[3, 4-b]pyridines: Potent inhibitors of glycogen synthase kinase-3 (GSK3). Bioorg Med Chem Lett 2003; 13(9): 1577-1580.
135. Haigh D, Hickey DMB, Liddle J, Slingsby BP, Ward RW, Witherington J. (Smithkline Beecham PLC, UK). Preparation of pyrazolopyridine derivatives as GSK3 inhibitors. WO 0345949 A1 20030605, 2003; pp. 47.
136. Rawlings DA, Witherington J. (Smithkline Beecham P.L.C. UK). Preparation of pyrazolo[3, 4-cipyridines as GSK3 inhibitors. WO 0250073 A1 20020627, 2001 pp. 31.
137. Bordas VJE, Ward RW, Witherington J. New (1-H-indazol-3-yl)-amide derivatives useful for the treatment of conditions e.g. diabetes, chronic neurodegencrative conditions such as Alzheimer's disease, Parkinson's disease. WO 0351847 A1 20030626, 2003; pp. 23.
138. Ter Haar E, Swenson L, Green J, Arnost MJ. (Vertex Pharmaceuticals Incorporated, USA). Preparation of 3-aminopyrazolo[3, 4-c]pyridazines as inhibitors of glycogen synthase kinase-3 and crystal structures of GSK3.beta. protein and protein complexes. WO 0288078 A2 20021107, 2002, pp. 778.
139. Witherington J, Bordas V, Haigh D, Hickey DMB, Ife RJ, Rawlings AD, et a[. 5-Aryl-pyrazolo[3, 4-b]pyridazines: Potent inhibitors of glycogen synthase kinase-3 (GSK3). Bioorg Med Chem Lett 2003; 13(9): 1581-1584.
140. Kohara T, Fukunaga K, Fujimura M, Hanano T, Okabe H. (Mitsubishi Pharma Corporation, Japan). Preparation of dihydropyrazolopyridines and pharmaceutical use based on strong and selective inhibition of glycogen synthase kinase-3 beta. WO 0262795 A2 20020815, 2002; pp. 228.
141. Ortega MA, Montoya ME, Zarranz B, Jaso A, Aldana I, Leclerc S, et al. Pyrazolo[3, 4-b]quinoxalines. A new class of cyclin-Dependent kinases inhibitors. Bioorg Med Chem 2002; 10(7): 2177-2184.
142. Scaffold hopping and optimization towards libraries of glycogen synthase kinase-3 inhibitors. Naerum L, Norskov-Lauritsen L, Olesen PH. Bioorg Med Chem Lett 2002; 12(11): 1525-1528.
143. Olesen PH, Sørensen AR, Ursø B, Kurtzhals P, Bowler AN, Ehrbar U, et al. Synthesis and in Vitro Characterization of 1-(4-Aminofurazan-3-yl)-5-dialkylaminomethyl-1H-[1, 2, 3]triazole-4-carboxylic Acid Derivatives. A New Class of Selective GSK3 Inhibitors J Med Chem 2003; 46(15): 3333-3341.
144. Olesen PH, Kurtzhals P, Worsaae H, Hansen BF, Sorensen AR, Bowler AN. (Novo Nordisk A/S, Den.). Preparation of furazanyltriazole derivatives as glycogen synthase kinase-3 (GSK3) inhibitors. WO 0232896 A1 20020425, 2002; pp. 71.
145. Martinez A, Alonso M, Castro A, Perez C, Moreno FJ. First Non-ATP Competitive Glycogen Synthase Kinase 3.beta. (GSK3.beta.) Inhibitors: Thiadiazolidinones (TDZD) as Potential Drugs for the Treatment of Alzheimer's Disease. J Med Chem 2002; 45(6): 1292-1299.
146. Martinez A, Castro A, Perez C, Cascon MA, Diaz I, Moreno FJ, et al. (Spain) Heterocyclic inhibitors of glycogen synthase kinase GSK3. WO 0185685 A1 20011115, 2001; pp. 31.
147. Fisher A. Therapeutic strategies in Alzheimer's disease: M1 muscarinic agonists. Jpn J Pharmacol 2000; 84: 101-112.
148. Forlenza OV, Spink JM, Dayanandan R, Anderton BH, Olesen OF, Lovestone S. Muscarinic agonist reduce tau phosphorylation in non-neuronal cells via GSK3beta inhibition and in neurons. J Neural Transm 2000; 107: 1201-1212.
149. Choquette D, Davies RJ, Wannamaker MW. (Vertex Pharmaceuticals, Inc. USA). Pyrimidine-based and quinazoline-based compounds useful as GSK3 inhibitors. WO 0349739 A1 20030619, 2003; pp. 102.
150. Green J, Arnost MJ, Pierce A. (Vertex Pharmaceuticals Incorporated, USA). Preparation of pyrazolone derivatives as inhibitors of GSK3, Aurora-2 and CDK-2. WO 0311287 A1 20030213, 2003: Pp. 143.
151. Golec J, Pierard F, Charrier J-D, Bebbington D. (Vertex Pharmaceuticals Incorporated, USA). Pyrazole compounds useful as protein kinase inhibitors, and therapeutic use thereof. WO 0250066 A2 20020627, 2002; pp. 87.
152. Bebbington D, Knegtel R, Golec JMC, Li P, Davies R, Charrier J-D. (Vertex Pharmaceuticals Incorporated, USA). Preparation of pyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease. WO 0222608 A1 20020321, 2002; pp. 356.
153. Davies R, Bebbington D, Knegtel R, Wannamaker M, Li P, Forester C, et al. (Vertex Pharmaceuticals Incorporated, USA). Preparation of pyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease. WO 0222607 A1 20020321, 2002, pp. 373.
154. Bebbington D, Binch H, Knegtel R, Golec JMC, Patel S, Charrier J-D, et al. (Vertex Pharmaceuticals Incorporated, USA). Preparation of pyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease. WO 0222606 A1 20020321, 2002; pp. 355.
155. Golec JMC, Charrier J-D, Knegtel R, Bebbington D, Davies R, Li P. (Vertex Pharmaceuticals Incorporated, USA). Preparation of pyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease. WO 0222605 A1 20020321, 2002; pp. 357.
156. Davies R, Bebbington D, Binch H, Knegtel R, Golec JMC, Patel S, et al. (Vertex Pharmaceuticals Incorporated, USA). Preparation of 3-(4-pyrimidinylamino)pyrazole derivatives as protein kinase inhibitors, especially of Aurora-2 and GSK3, for treating cancer, diabetes and Alzheimer's disease. WO 0222604 A1 20020321, 2002; pp. 357.
157. Davies R, Li P, Golec J, Bebbington D. (Vertex Pharmaceuticals Incorporated, USA), Preparation of pyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease. WO 0222603 A1 20020321, 2002; pp. 406.
158. Knegtel R, Bebbington D, Binch H, Golec J, Patel S, Charrier J-D, et al. (Vertex Pharmaceuticals Incorporated, USA). Preparation of pyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease. WO 0222601 A1 20020321, 2002; pp. 376.
159. Bebbington D, Knegtel R, Binch H, Golec JMC, Li P, Charrier J-D. (Vertex Pharmaceuticals Incorporated, USA). Preparation of triazolamines as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease. WO 0222602 A2 20020321, 2002; pp. 377.
160. Freyne EJE, Buijnsters PJJA, Willems M, Embrechts WCJ, Love CJ, Janssen PAJ, et al. (Janssen Pharmaceutica N.V. Belg.). Preparation of heteroarylamines as glycogen synthase kinase 3beta inhibitors. WO 0337891 A1 20030508, 2003; pp. 88.
161. Freyne EJE, Buijnsters PJJA, Willems M, Embrechts WCJ, Janssen PAJ, Lewi PJ, et al. (Janssen Pharmaceutica N.V. Belg.). Preparation of aminobenzamide derivatives as glycogen synthase kinase 3.beta. inhibitors. WO 0337877 A1 20030508, 2003; pp. 87.
162. Freyne EJE, Buijnsters PJJA, Willems M, Embrechts WCJ, Lacrampe JFA, Janssen PAJ, et al. (Janssen Pharmaceutica N.V, Belg.). Preparation of heterocyclecarboxamide derivatives as glycogen synthase kinase 3-beta inhibitors. WO 0337869 A1 20030508, 2003; pp. 70.
163. Gallet T, Lardenois P, Lochead WA, Nedelec A, Marguerie S, Saady M, et al. (Sanofi-Synthelabo, Fr.; Mitsubishi-Tokyo Pharmaceuticals, Inc.). Preparation of 2-pyrimidinyl-6, 7, 8, 9-tetrahydro-pyrimido[1, 2-a]pyrimidin-4-ones and 7-pyrimidinyl-2, 3-dihydro-imidazo[1, 2-a]pyrimidin-5(1H)-ones for treatment of neurodegenerative disease. EP 1295884 A1 20030326, 2003; pp. 30.
164. Gallet T, Lochead A, Nedelec A, Saady M, Yaiche P. (Sanofi-Synthelabo, Fr.; Mitsubishi-Tokyo Pharmaceuticals, Inc.). 1-Alkyl-, 1-heteroarylalkyl- and 1-aralkyl-7-pyridin-4-yl-2, 3-dihydroimidazo [1, 2-a]pyrimidin-5(1H)-ones as inhibitors of GSK3beta EP 1184385 A1 20020306, 2002; pp. 17.
165. Almario-Garcia A, Frost JR, Li A-T. (Sanofi-Synthelabo, Fr.; Mitsubishi-Tokyo Pharmaceuticals, Inc.). Preparation of 2-[(heteroaryl)alkylamino]pyrimidones as GSK3beta inhibitors. EP 1136491 A1 20010926, 2001; pp. 12.
166. Almario-Garcia A, Frost JR, Li A-T. (Sanofi-Synthelabo, Fr.; Mitsubishi-Tokyo Pharmaceuticals, Inc.). Preparation of 2-[(indanylamino]pyrimidones and 2-[tetrahydronaphthalenylamino] pyrimidones as GSK3beta inhibitors. EP 1136486 A1 20010926, 2001; pp. 12.
167. D'Orchymont H, Lavrador K, Schoenjes B, Van Dorsselaer V. (Sanofi-Synthelabo, Fr.; Mitsubishi-Tokyo Pharmaceuticals, Inc.). Preparation of 2-aminophenylpyrimidones as GSK3beta inhibitors. EP 1136485 A1 20010926, 2001; pp. 21.
168. Almario-Garcia A, Frost JR, Li A-T, Ando R, Watanabe K. (Sanofi-Synthelabo, Fr.; Mitsubishi-Tokyo Pharmaceuticals, Inc.). Preparation of 2-(arylalkylamino)pyrimidones as GSK3beta inhibitors. EP 1136484 A1 20010926, 2001; pp. 24.
169. Almario-Garcia A, Frost JR, Li A-T, Ando R, Shoda A. (Sanofi-Synthelabo, Fr.; Mitsubishi-Tokyo Pharmaceuticals, Inc.). Preparation of 2-(piperazinyl)pyrimidones as GSK3beta inhibitors. EP 1136483 A1 20010926, 2001; pp. 18.
170. Almario-Garcia A, Frost JR, Li A-T, Ando R, Watanabe K. (Sanofi-Synthelabo, Fr.; Mitsubishi-Tokyo Pharmaceuticals, Inc.). Preparation of 2-amino-3-alkyl-pyrimidones as GSK3beta inhibitors. EP 1136482 A1 20010926, 2001; pp. 20.
171. Almario-Garcia A, Frost JR, Li A-T. (Sanofi-Synthelabo Fr Mitsubishi-Tokyo Pharmaceuticals, Inc.). Preparation of 2-(indolylalkylamino)pyrimidone derivatives as gsk3beta inhibitors. EP 1136099 A1 20010926, 2001; pp. 14.
172. Ahlijanian MK, Cooper CB, Helal CJ, Lau L-F, Menniti FS, Sanner MA, et al. (Pfizer Products Inc., USA). Preparation of acylamino-imidazoles as inhibitors of cdk5, cdk2, and GSK3. WO 0210141 A1 20020207, 2002; pp. 70.
173. Cooper CB, Helal CJ, Sanner MA. (Pfizer Products Inc., USA). Thiazole derivatives and their use as cdk inhibitors, including combinations and pharmaceutical compositions. EP 1256578 A1 20021113, 2002; pp. 32.
174. Bowler AN, Olesen PH, Sorensen AR, Hansen BF, Worsaae H, Kurtzhals P. (Novo Nordisk A/S, Den.). Preparation of 2, 4-diaminothiazoles as GSK3 inhibitors. WO 0156567 A1 20010809, 2001; pp. 94.
175. Bowler AN, Hansen BF. (Novo Nordisk A/S, Den.). Preparation of novel 2, 4-diaminothiazoles as glycogen synthase kinase-3 (GSK3) inhibitors. WO 0311843 A1 20030213, 2003; pp. 65.
176. Harris PA, Wang TY. (Smithkline Beecham Corporation, USA). Preparation of triarylimidazole as inhibitor of glycogen synthase kinase-3. WO 0324447 A1 20030327, 2003; pp. 26.
177. Berg S, Hellberg S. (Astrazeneca AB, Swed.). Preparation of pyrazine-2-carboxamides as glycogen synthase kinase-3 (GSK3) inhibitors. WO 0304472 A1 20030116, 2003; pp. 158.
178. Berg S, Hellberg S. (Astrazeneca AB, Swed.). Preparation of 4-(imidazo[1, 2-a]pyridin-3-yl)-2-[4-(or 3-)(hetero)arylcarbonyl]anilinopyrimidines as glycogen synthase kinase-3 (GSK3) inhibitors. WO 0265979 A2 20020829, 2002; pp. 47.
179. Prevost G, Lonchampt M-O, Kim S, Morgan B, Ulibarri G, Thurieau C. (Societe De Conseils De Recherches Et D'applications Scientifiques (S..C..R..A..S.), Fr.). Pyrazolo[1, 5-a]-1 3, 5-triazine derivatives with activity as cyclin-dependent kinase (CDK) and glycogen synthase kinase-3 (GSK3) inhibitors, and their preparation, pharmaceutical compositions, and use as, e.g., antiproliferative agents. WO 0250079 A1 20020627, 2002; pp. 49.
180. Monia BP, McKay R, Butler MM, Wyatt JR. (Isis Pharmaceuticals, Inc. USA), Antisense modulation of glycogen synthase kinase 3 alpha expression. WO 0152865 A1 20010726, 2001; pp. 115.
181. Eldar-Finkleman, H. (Ramot University Authority for Applied Research & Industrial Development Ltd., Israel). Glycogen synthase kinase-3 inhibitors. WO 0149709 A1 20010712, 2001, pp. 49.
182. Eldar-Finkelman H. (Ramot University Authority for Applied Research & Industrial Development Ltd., Israel). Glycogen synthase kinase-3 inhibitor peptides, inhibitor design, and therapeutic use. US 2002147146 A1 20021010, 2002; pp. 34.
183. Kahn B. Type 2 diabetes: When insulin secretion fails to compensate for insulin resistance. Cell 1988; 92: 593-596.
184. Taylor S. Deconstructing type 2 diabetes. Cell 1999; 97: 9-12.
185. Olefsky J, Nolan J. Insulin resistance and non-insulin-dependent diabetes mellitus: Cellular and molecular mechanisms. Am J Clin Nutr 1995; 61(suppl), 980S-986S.
186. Shulman, G. Cellular mechanisms of insulin resistance. J Clin Invest 2000; 106, 171-176.
187. Saltiel A. The molecular and physiological basis of insulin resistance: Emerging implications for metabolic and cardiovascular diseases. J Clin Invest 2000; 106: 163-164.
188. Kolterman O, Insel J, Saekow M, Olefsky J. Mechanisms for insulin resistance in obesity: Evidence for receptor and post-receptor defects. J Clin Invest 1980; 65: 1272-1284.
189. Reaven G. Role of insulin resistance in human disease (syndrome X): An expanded definition. Annu Rev Med 1993; 44: 121-131.
190. Embi N, Rylatt D, Cohen P. Glycogen synthase kinase-3 from rabbit skeletal muscle. Separation from cyclic-AMP-dependent protein kinase and phosphorylase kinase. Eur J Biochem 1980; 107: 519-527.
191. Fisher J, Nolte L, Kawanaka K, Han D, Jones T, Holloszy J. Glucose transport rate and glycogen synthase activity both limit skeletal msucle glycogen accumulation. Am J Physiol Endocrinol Metab 2002; 282: E1214-E1221.
192. 13C nuclear magnetic resonance spectroscopy. N Engl J Med 1990; 22: 223-228.
193. Thornburn A, Gumbiner B, Bulacan F, Brechtel G, Henry R. Multiple defects in muscle glycogen synthase activity contribute to reduced glycogen synthesis in non-insulin dependent diabetes mellitus. J Clin Invest 1991; 87: 489-495.
194. Henry R, Ciaraldi T, Abrams-Carter L, Mudaliar S, Park K, Nikoulina S. Glycogen synthase activity is reduced in cultured skeletal muscle cells of non-insulin-dependent diabetes mellitus. J Clin Invest 1996; 98: 1231-1236.
195. Henry R, Ciaraldi T, Mudaliar S, Abrams L, Nikoulina S. Acquired defects of glycogen synthase activity in cultured human skeletal msucle cells. Diabetes 1996; 45: 400-407.
196. Nikoulina S, Ciaraldi T, Mudaliar S, Mohideen P, Carter L, Henry R. Potential role of glycogen synthase kinase-3 in skeletal muscle insulin resistance of type 2 diabetes. Diabetes 2000; 49: 263-270.
197. Saran A. Antidiabetic effects of lithium. J Clin Psychiatry 1982, 43, 383-384.
198. Rossetti, L. Normalization of insulin sensitivity with lithium in diabetic rats. Diabetes 1989, 38, 648-652.
199. Rodriquez-Gil J, Guinovar J, Bosch F. Lithium restores glycogen synthesis from glucose in hepatocytes from diabetic rats. Arch Biochem Biophysics 1993; 301: 411-415.
200. Orena S, Torchia A, Garafalo R. Inhibition of glycogen-synthase kinase 3 stimulates glycogen synthase and glucose transport by distinct mechanisms in 3T3-L1 adipocytes. J Biol Chem 2000; 275: 15765-15772.
201. Nikoulina S, Ciaraldi T, Mudalier S, Carter L, Johnson K, Henry R. Inhibition of glycogen synthase kinase 3 improves insulin action and glucose metabolism in human skeletal muscle. Diabetes 2002; 51: 2190-2198.
202. Ionescu E, Sauter J, Jeanrenaud B. Abnormal oral glucose tolerance in genetically obese (fa/fa) rats. Am J Physiol 1985; 248: E500-506.
203. Terrettaz J, Assimacopoulos-Jeannet F, Jeanrenaud B. Severe hepatic and peripheral insulin resistance as evidenced by euglycemic clamps in genetically obese fa/fa rats. Endocrinol 1986; 118: 674-678.
204. Munoz M, Barbera A, Dominguez J, Fenandez-Alvarez J, Gomis R, Guinovart J. Effects of tungstate, a new potential oral antidiabetic agent, in zucker diabetic fatty rats. Diabetes 2001; 50: 131-139.
205. Cline G, Johnson K, Regittnig W, Perret P, Tozzo E, Xiao E, et al. Effects of novel GSK3 inhibitors on insulin-stimulated glucose metabolism in Zucker Diabetic Fatty (fa/fa) rats. Diabetes 2002; 51: 2903-2910.
206. Henriksen E, Kinnick T, Teachey M, O'Keefe M, Ring D, Johnson K, et al. Modulation of muscle insulin resistance by selective inhibition of GSK3 in Zucker diabetic fatty rats. Am J Physiol Endocrinol Metab 2003; 284: E892-E900.
207. Fiedorek F. Rodent genetic models for obesity and non-insulin-dependent diabetes mellitus. In, Diabetes Mellitus Ed, LeRoith D, Taylor S, Olefsky J, Lippencott-Raven Publishing 1996; pp. 604-618.
208. Luo J, Quan J, Tsai J, Hobensack C, Sullivan C, Hector R, et al. Nongenetic mouse models of non-insulin-dependent diabetes mellitus. Metabolism 1998; 47: 663-668.
209. Eldar-Finkelman H, Schreyer S, Shinohara M, LeBoeuf R, Krebs E. Increased glycogen synthase kinase-3 activity in diabetes- and obesity-prone C57BL/6j mice. Diabetes 1999; 48: 1662-1666.
210. Holder J, Brockie S, Lister C. ob/ob mice exhibited an increase in muscle GSK3 activity which correlated with reduced GS activity and glucose intolerance. Keystone Symposia, Taos, New Mexico Feb. 16-22, 2000; Abstract #416.
211. Sparks J, Phung T, Bolognino M, Cianci J, Khurana R, Peterson R, et al. Lipoprotein alterations in 10- and 20-week-old Zucker Diabetic Fatty rats: Hyperinsulinemic vs insulinopenic hyperglycemia. Metabolism 1998; 47: 1315-1324.
212. Anai M, Funaki M, Ogihara T, Terasaki J, Inukai K, Katagiri H, et al. Altered expression levels and impaired steps in the pathway to phosphatidylinositol 3-kinase activation via insulin receptor substrates 1 and 2 in Zucker fatty rats. Diabetes 1998; 47: 13-23.
213. Brozinick J, Misener E, Ni B, Ryder J. Diabetes 2000; 49(S1): 1363-P.
214. Hansen B. Primate animal models of type 2 diabetes. In, Diabetes Mellitus: A Fundamental and Clinical Text, Ed LeRoith D, Taylor S, Olefsky J, Lippincott Williams & Wilkins Publishing 2000; pp. 734-745
215. Lochhead P, Coghlan M, Rice S, Sutherland C. Inhibition of GSK3 selectively reduces glucose-6-phosphatase and phosphoenolpyruvate carboxykinase gene expression. Diabetes 2001; 50: 937-946.
216. Finegood D, McArthur M, Kojwang D, Thomas M, Topp B, Leonard T, et al. Beta-cell mass dynamics in Zucker Diabetic Fatty rats: Rosiglitazone prevents the rise in net cell death Diabetes 2001; 50: 1021-1030.
217. Sun G, Kelly S, Zhao H, Cheng D, Luo J, Harrison S, et al. GSK-3β inhibitor (CHIR98025) reduces infarct size following 90min MCAO. Society of Neuroscience, 32nd Ann. Meeting, Orlando FL Nov. 2-7, 2002; Program #697.7.
218. Bennett C, Ross S, Longo K, Bajnok L, Hemati N, Johnson K, et al. Regulation of Wnt Signalling during Adipogenesis. J Biol Chem 2002;277:30998.
219. Yuan M, Wang X, Melendez PA, Guo Y, Hansen L, Lee J, et al. Heterozygous Deletion of GSK3β Reduces Fat Mass in Mice American Diabetes Assoc 63rd Scientific Sessions June 13-17 2003; New Orleans, Abstract 1701-P.
220. McCormack JG, Westergaard N, Kristiansen M, Brand CL, Lau J. Pharmacological approaches to inhibit endogenous glucose production as a means of anti-diabetic therapy. Curr Pharm Design 2001; 7(14): 1451-74.
221. Wagman AS, Nuss JM. Current therapies and emerging targets for the treatment of diabetes. Curr Pharm Design 2001; 7(6): 417-50.
222. Weyer C, Maggs DG, Young AA, Kolterman OG. Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: A physiological approach toward improved metabolic control. Curr Pharm Design 2001; 7(14): 1353-73.